

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50412/020003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/517,563
		Applicant	Eva Steiness
		371(c) Date	July 8, 2005
		Group	1644
(37 C.F.R. § 1.98(b))		IDS Filed	March 18, 2010

U. S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	6,191,102	Feb. 20, 2001	DiMarchi et al.
	6,268,343	Jul. 31, 2001	Knudsen et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	EP 1525219 B1	May 27, 2009	E.P.O.	
	EP 2028192 A1	Feb. 25, 2009	E.P.O.	
	WO 00/09666	Feb. 24, 2000	W.I.P.O.	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Behme et al., "Glucagon-Like Peptide 1 Improved Glycemic Control in Type 1 Diabetes," <i>BMC Endocrinol. Disord.</i> 3:3, 2003.
	Buse et al., "Progressive use of Medical Therapies in Type 2 Diabetes," <i>Diabetes Spectrum</i> 13(4):211-220, 2000.
	Edvelli et al., "Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå +7)," <i>Endocrinology</i> 140:778-783, 1999.
	EMEA Humalog Information: European Public Assessment Report (EPAR) and Scientific Discussions, 2006
	Fineman et al., "AC2993 (Synthetic Exendin-4) Added to Existing Metformin (Met) and/or Sulfonylurea (SFU) Treatment Improved Glycemic Control in Patients with Type 2 Diabetes (DM2)," <i>Diabetes</i> 51 (Supplement 2):A85, Abstract 343-OR, Abstract Book 62 nd Scientific Sessions, June 14-18, 2002.
	Greig et al., "Once Daily Injection of Exendin-4 to Diabetic Mice Achieves Long-Term Beneficial Effects on Blood Glucose Concentrations," <i>Diabetologia</i> 42:45-50, 1999.
	Holst, "Glucagon-Like Peptide-1, a Gastrointestinal Hormone with a Pharmaceutical Potential," <i>Curr. Med. Chem.</i> 6:1005-1017, 1999.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50412/020003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/517,563
(37 C.F.R. § 1.98(b))		Applicant	Eva Steiness
		371(c) Date	July 8, 2005
		Group	1644
		IDS Filed	March 18, 2010

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Hui et al., "The Short Half-Life of Glucagon-Like Peptide-1 in Plasma Does Not Reflect Its Long-Lasting Beneficial Effects," <i>Eur. J. Endocrinol.</i> 146:863-869, 2002.
	Owens et al., "Insulins Today and Beyond," <i>The Lancet</i> 358:739-746, 2001.
	Petersen et al., "ZP10- A New GLP-1 Agonist that Prevents Diabetes Progression and Increases Insulin mRNA Expression in <i>db/db</i> Mice," 38 th Annual Meeting of the European Association for the Study of Diabetes (EASD), Budapest, Hungary, September 1-5, 2002, <i>Diabetologia</i> 45 (Suppl. 1):A147, Abstract No. 447, 2002.
	Thorkildsen et al., "ZP10- A New GLP-1 Agonist that Prevents Diabetes Progression and Increases Insulin mRNA Expression in <i>db/db</i> Mice," 38 th Annual Meeting of the European Association for the Study of Diabetes (EASD), Budapest, Hungary, September 1-5, 2002, Poster Presentation.
	Thorkildsen et al., "ZP10- A New GLP-1 Agonist that Increases Insulin mRNA Expression," Nedergaard Symposium, Odense, Denmark, January 24, 2002 (Abstract).
	Thorkildsen et al., "ZP10- A New GLP-1 Agonist that Increases Insulin mRNA Expression," Nedergaard Symposium, Odense, Denmark, January 24, 2002, Poster Presentation.
	Tourrel et al., "Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the β -Cell Mass During the Prediabetic Period with Glucagon-Like Peptide-1 or Exendin-4," <i>Diabetes</i> 51:1443-1452, 2002.
	Wang et al., "Glucagon-Like Peptide-1 Treatment Delays the Onset of Diabetes in 8 Week-Old <i>db/db</i> Mice," <i>Diabetologia</i> 45:1263-1273, 2002.
	Xu et al., "Exendin-4 Stimulates Both β -Cell Replication and Neogenesis, Resulting in Increased β -Cell Mass and Improved Glucose Tolerance in Diabetic Rats," <i>Diabetes</i> 48:2270-2276, 1999.
	Zander et al., "Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes," <i>Diabetes Care</i> 24(4):720-725, 2001.
	European Search Report and European Search Opinion for European Patent Application No. 08018668 completed January 14, 2009.
	Notice of Opposition and Opposition from European Patent No. 1626219, filed February 26, 2010.
	Opposition from European Patent No. 1626219, filed February 26, 2010.
	International Search Report for PCT/DK2003/00463, completed September 30, 2003, mailed October 22, 2003.
	International Preliminary Examination Report for PCT/DK2003/00463, completed September 20, 2004.

Lined-through refs not properly cited, e.g., authors, publication dates.

EXAMINER /Gerald Ewoldt/	DATE CONSIDERED 06/13/2010
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./